A Phase III Randomized, Open-Label Clinical Trial of BBI-608 Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer

Trial Profile

A Phase III Randomized, Open-Label Clinical Trial of BBI-608 Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer

Discontinued
Phase of Trial: Phase III

Latest Information Update: 13 Jul 2017

At a glance

  • Drugs Napabucasin (Primary) ; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Boston Biomedical
  • Most Recent Events

    • 07 Jul 2017 Status changed from recruiting to discontinued.
    • 10 Jun 2017 Biomarkers information updated
    • 19 Dec 2016 Planned primary completion date changed from 1 Oct 2019 to 1 Nov 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top